Navigation Links
Cause and potential treatment found for cancer drug's kidney toxicity
Date:6/2/2011

AUGUSTA, Ga. Scientists may have a way to make the powerful cancer drug cisplatin less toxic to the kidneys and more effective against some cancers.

The chemotherapeutic agent used in combination with other drugs for a variety of cancers, results in kidney damage or failure in about 30 percent of users, although the mechanism has been unclear. The most physicians can do today to protect the kidneys is advise patients to drink more water.

The relatively simple, highly reactive compound tends to accumulate in the kidneys, said Dr. Navjotsingh Pabla, postdoctoral fellow at Georgia Health Sciences University and first author on the study in The Journal of Clinical Investigation. "The kidneys can take it up, but they have trouble removing it, so it just accumulates," he said.

The kidneys' endless workload of filtering some substances while resorbing others leaves them vulnerable to injury, one of the reasons the kidneys are the first organ to shut down when a patient is critically ill, said Dr. Zheng Dong, GHSU cell biologist, Career Research Scientist at the Charlie Norwood Veterans Affairs Medical Center in Augusta and the study's senior author. "Any stress to the cell can injure it," Dong said.

The scientists have shown in mice with tumors as well as human cancer cells in culture that cisplatin highly activates protein kinase C delta; protein kinases regulate other proteins by adding phosphates to them that can change their function. They've further shown that protein kinase C delta is a key mediator of cell death in kidneys and important to cancer cell survival.

The dichotomy appears useful because they've also shown that a drug, already in clinical trials for its potential in protecting brain cells following stroke, blocks the kidney destruction. In fact, protein kinase inhibitors in mice with tumors, enhanced breast and ovarian cancer treatment.

"Normal cells may not depend on this protein for survival and growth so if you remove it, there don't appear to be major negative consequences," Pabla said. The findings point toward using protein kinase C inhibitors as an adjunct therapy for patients experiencing kidney problems and potentially for all cancer patients treated with cisplatin if the enhanced efficacy finding continues to hold up, Dong said.

The scientists note that reducing the cisplatin dose decreases kidney toxicity but also decreases its efficacy and may leave the patient resistant to even higher doses of the drug. In the more than 30-year history with cisplatin, related drugs, such as carboplatin, have been developed to circumvent kidney damage, but those drugs tend to have more limited use, be less effective and/or have additional side effects. In more recent years, the focus has been on trying to protect the kidneys.

Next steps include working with chemists to see if an even more effective inhibitor can be developed.


'/>"/>

Contact: Toni Baker
tbaker@georgiahealth.edu
706-721-4421
Georgia Health Sciences University
Source:Eurekalert  

Related medicine news :

1. GW researchers show host Mta1 gene is required for optimal survival of schistosome parasites, a leading global cause of cancer
2. Cosmetics can cause serious adverse effects
3. Heart scientists discover protein that may be 1 cause of heart failure
4. Dietary inorganic nitrate may reduce heart dysfunction caused by powerful anti-cancer drug
5. Newer Epilepsy Meds Less Likely to Cause Birth Defects: Study
6. A gene that fights cancer, but causes it too
7. Chiropractic Spinal Manipulation Wont Cause Chest Injuries, Study Contends
8. Mayo Clinic finds new genetic cause of neurodegeneration
9. Morning Heart Attacks Cause More Damage, Study Finds
10. Increased computer use by adolescents cause for concern
11. Wrestlers Quick Weight Loss May Cause Mental Confusion
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cause and potential treatment found for cancer drug's kidney toxicity
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: